百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

交易中 07-18 14:34:04

181.300

-2.000

-1.09%

最高182.500	最低176.000	成交量617.89万
今开179.000	昨收183.300	日振幅3.55%
总市值2,792亿	流通市值2,584亿	总股本15.40亿
成交额11.07亿	换手率0.43%	流通股本14.25亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":181.3,"timestamp":1752820443637,"preClose":183.3,"halted":0,"volume":6178889,"delay":0,"floatShares":1425000000,"shares":1540000000,"eps":-3.6975134218705854,"marketStatus":"交易中","change":-2,"latestTime":"07-18 14:34:04","open":179,"high":182.5,"low":176,"amount":1106772281,"amplitude":0.035461,"askPrice":181.4,"askSize":3400,"bidPrice":181.2,"bidSize":15500,"shortable":3,"etf":0,"ttmEps":-2.235918809456532,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752826200000},"marketStatusCode":2,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":183.3,"openAndCloseTimeList":[[1752802200000,1752811200000],[1752814800000,1752825600000]],"volumeRatio":1.219989,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":248.95,"timestamp":1752820403000,"preClose":250.85,"halted":0,"volume":1834100,"delay":0,"premium":"-33.34"}},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"2552432784","title":"鹏华基金苏俊杰旗下鹏华上证科创板100ETF中报最新持仓，重仓百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2552432784","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552432784?lang=zh_cn&edition=full","pubTime":"2025-07-18 07:10","pubTimestamp":1752793826,"startTime":"0","endTime":"0","summary":"证券之星消息，7月18日鹏华基金旗下苏俊杰管理的鹏华上证科创板100交易型开放式指数基金公布中报，近1年净值增长率46.46%。与上一季度相比，该基金前十大重仓股新增华虹公司，中科飞测，安集科技，纳芯微；并对百济神州增仓3.02万股，为该基金第一大重仓股；恒玄科技，绿的谐波，铂力特，乐鑫科技等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800004958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK1588","LU0588546209.SGD","LU0307460666.USD","588120","BK1500","BK1583","BK1161","399300","000001.SH","688235","159982","LU1969619763.USD","BK0239","06160"],"gpt_icon":0},{"id":"2552871484","title":"全网打捞：下一个大BD","url":"https://stock-news.laohu8.com/highlight/detail?id=2552871484","media":"阿基米德Biotech","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552871484?lang=zh_cn&edition=full","pubTime":"2025-07-17 21:06","pubTimestamp":1752757573,"startTime":"0","endTime":"0","summary":"今天，你不能轻视任何一家Biotech，因为一旦达成BD就翻身。据医药魔方，2025H1，中国创新药License out总金额接近660亿美元，赶超2024全年BD交易总额。今天我们越过旧山丘，与新世界撞个满怀，在可见范围内尽力打捞下一个潜在的重磅BD。HLX43进展神速，获多国批准开展NSCLC国际多中心II期临床，是全球首个进入临床II期的PD-L1 ADC，引领强效低毒ADC全球开发进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717211513a4513799&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717211513a4513799&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2495084118.USD","LU1328615791.USD","LU1655091616.SGD","BK0188","BK0060","LU1997245094.SGD","LU1064130708.USD","02696","LU1997245177.USD","01801","BK0028","LU1997244956.HKD","BK0196","LU2328871848.SGD","BK0012","01093","01877","LU1969619763.USD","06160","LU2488822045.USD","BK0239","LU0405327494.USD","BK0183","LU2148510915.USD","600276","LU0405327148.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2552438772","title":"百济神州07月17日获主力大幅加仓2.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552438772","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552438772?lang=zh_cn&edition=full","pubTime":"2025-07-17 16:15","pubTimestamp":1752740140,"startTime":"0","endTime":"0","summary":"07月17日, 百济神州股价涨10.62%，报收183.30元，成交金额20.6亿元，换手率0.81%，振幅10.80%，量比2.09。百济神州今日主力资金净流入2.2亿元，连续5日净流入，上一交易日主力净流入2270.2万元。近一年数据显示，该股主力连续5日净流入后，次日上涨概率为60.00%，平均涨幅为2.51%。该股近5个交易日上涨19.44%，主力资金累计净流入3.4亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入3.7亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717171409a6af6b5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717171409a6af6b5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1500","LU0588546209.SGD","LU0307460666.USD","BK1161","LU2328871848.SGD","LU1969619763.USD","06160","BK1583"],"gpt_icon":0},{"id":"2552058901","title":"创新药再获热炒 恒生医疗ETF涨4.37% 乐普生物(02157)涨两成 机构称价值重估驱动行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2552058901","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552058901?lang=zh_cn&edition=full","pubTime":"2025-07-17 14:08","pubTimestamp":1752732500,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药再获热炒，恒生医疗ETF暂涨4.37%，乐普生物-B 涨20.55%，康诺亚-B涨14.7%，康方生物涨11.75%，三生制药涨11.09%，百济神州涨10.02%，科伦博泰生物-B涨9.29%，金斯瑞生物科技涨8.45%，先声药业涨8.44%。国家医保局于本周二宣布启动第11轮国家药品集采，涉及55种药品。医院需在7月16日至7月31日期间报告采购量。值得注意的是，《通知》首次附上了68种符合评价标准但未纳入第11批VBP的产品名单，并具体说明了排除原因。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1962441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348783233.USD","LU1969619763.USD","HK0000306701.USD","LU0307460666.USD","LU1794554557.SGD","LU0196878994.USD","09926","159992","LU0417516571.SGD","BK1500","BK1574","BK1583","02162","BK1588","LU0588546209.SGD","513060","01530","HK0000306685.HKD","IE00B543WZ88.USD","HK0000320264.USD","06990","BK1161","IE00BPRC5H50.USD","BK1576","LU2328871848.SGD","01548","02096","LU2488822045.USD","BK1587","06978","HK0000320223.HKD","LU1720050803.USD","06160","02157","BK1191","LU0348784397.USD","BK1141","IE00B5MMRT66.SGD","BK1593"],"gpt_icon":0},{"id":"2552412721","title":"百济神州-U股价微跌0.56% 生物制药板块活跃度受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2552412721","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552412721?lang=zh_cn&edition=full","pubTime":"2025-07-17 01:56","pubTimestamp":1752688566,"startTime":"0","endTime":"0","summary":"百济神州-U7月16日收盘报239.94元，较前一交易日下跌0.56%。当日股价波动区间为237.79元至246.28元，成交金额达5.01亿元。该公司属于生物制品行业，专注于创新型分子靶向药物和肿瘤免疫药物的研发。作为一家全球性生物科技公司，百济神州在肿瘤治疗领域拥有多个在研产品管线。7月16日数据显示，百济神州-U主力资金净流出2927.45万元。该股当前总市值为3694.74亿元，流通市值276.06亿元。风险提示：股市有风险，投资需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","06160","ONC","688235"],"gpt_icon":0},{"id":"2551140802","title":"小细胞肺癌或将迎来首个BiTE新疗法，百济神州塔拉妥单抗申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2551140802","media":"新浪医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551140802?lang=zh_cn&edition=full","pubTime":"2025-07-16 19:15","pubTimestamp":1752664513,"startTime":"0","endTime":"0","summary":"2025年7月16日，国家药品监督管理局药品审评中心网站显示，百济神州的注射用塔拉妥单抗上市申报获受理。SCLC约占所有肺癌病例的15%,，其中大约70%的SCLC患者初始诊断时即为ES-SCLC。据悉，塔拉妥单抗由安进公司研发。未来，双方将继续拓展塔拉妥单抗的应用范围，加速更多适应症申报上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716192041a44e9ea7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716192041a44e9ea7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","688235","BK4526","06160","ONC"],"gpt_icon":0},{"id":"2551576142","title":"高管减持迪哲医药另一面：全球化战略会是下个百济神州吗？【医药视界】","url":"https://stock-news.laohu8.com/highlight/detail?id=2551576142","media":"投资者网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551576142?lang=zh_cn&edition=full","pubTime":"2025-07-16 18:01","pubTimestamp":1752660075,"startTime":"0","endTime":"0","summary":"减持释放什么信号迪哲医药进入一个高层减持密集期。其中，吴清漪减持金额超1900万元，股份来源于股权激励及二级市场增持。截至目前，公司仍无控股股东、实际控制人。获批上市后，该药被成功纳入医保。公司表示，两款药品纳入医保目录后，销量大幅增加。最为市场熟知的，是百济神州的泽布替尼。受此因素，该药成功在欧美获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688192","BK4526","688235","06160","BK4139"],"gpt_icon":0},{"id":"2552124520","title":"每日卖空追踪 | 百济神州 07月16日卖空量成交43.94万股，卖空比例为8.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552124520","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552124520?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:30","pubTimestamp":1752654639,"startTime":"0","endTime":"0","summary":"百济神州北京时间07月16日，涨0.79%，卖空量成交43.94万股%，较上一交易日减少70.49%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716172841a44e637b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716172841a44e637b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","LU2328871848.SGD","BK1583","LU0588546209.SGD","06160","BK1161","LU1969619763.USD","BK1588","BK1500"],"gpt_icon":0},{"id":"2552124524","title":"百济神州07月16日获主力加仓2270.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552124524","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552124524?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:15","pubTimestamp":1752653739,"startTime":"0","endTime":"0","summary":"07月16日, 百济神州股价涨0.79%，报收165.70元，成交金额8.2亿元，换手率0.35%，振幅3.59%，量比0.89。百济神州今日主力资金净流入2270.2万元，连续4日净流入，上一交易日主力净流入3019.6万元。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为38.46%，平均涨幅为1.94%。该股近5个交易日上涨9.97%，主力资金累计净流入8822.2万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1.6亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716170355a6ad1222&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716170355a6ad1222&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU1969619763.USD","LU0307460666.USD","LU2328871848.SGD","BK1588","BK1583","BK1500","LU0588546209.SGD","06160"],"gpt_icon":0},{"id":"2551119280","title":"科创成长层改革推进 券商系统升级及风险揭示书签署有序展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2551119280","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551119280?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:13","pubTimestamp":1752635582,"startTime":"0","endTime":"0","summary":"上交所方面正组织风险揭示书签署工作，并修订相关指南，新增《科创板科创成长层企业股票投资风险揭示书必备条款》，明确未盈利企业存在的各类投资风险。上交所下发通知要求券商完善适当性管理工作，包括完成风险揭示书签署及系统准备，给予投资者充分阅读时间，并通过多种渠道开展投资者教育。上交所将持续督促券商并开展监督检查。7月14日，上交所举办专题培训会，120家券商330余名相关负责人参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688221","06160","000690.SH","688549","688316","688220","688702","688165","688387","688322","01877","688277","688197","688538","688512","09969","688443","688266","688192","688343","688561","688327","02402","BK0239","688382","688373","ONC","688176","688280","688256","688302","688515","688469"],"gpt_icon":0},{"id":"2551811340","title":"【券商聚焦】交银国际：当前港股创新药板块估值仍具吸引力","url":"https://stock-news.laohu8.com/highlight/detail?id=2551811340","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551811340?lang=zh_cn&edition=full","pubTime":"2025-07-16 09:15","pubTimestamp":1752628556,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际认为，当前港股创新药板块估值仍具吸引力：1）头部创新药企的前瞻市销率与熊市以来的历史均值基本持平，虽略高于美股可比公司、但营收增长预期亦远高于后者；2）目前港股龙头收入达峰时的市销率约3倍，个别公司仅有2倍左右，低于美股平均的4倍；3）1H25内资持续通过港股通加仓，但外资的创新药持仓处于底部。长期内保费和创新药支付规模有望呈数十倍增长。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1962312","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","BK1141","LU1807302812.USD","01801","BK1521","BK1515","LU0348825331.USD","01877","YANG","LU2039709279.SGD","LU0140636845.USD","LU1951186391.HKD","LU0348784397.USD","IE0008369823.USD","02616","IE00B543WZ88.USD","06160","HSTECH","02142","LU0327786744.USD","LU1226288170.HKD","BK4614","09688","06185","LU0039217434.USD","LU0359202008.SGD","HSCEI","LU1960683339.HKD","01177","09926","BK1576","LU0501845795.SGD","LU1008478684.HKD","159992","LU0880133367.SGD","LU1969619763.USD","IE0008368742.USD","IE00B5MMRT66.SGD","LU0359201612.USD","LU1226287875.USD","03329","LU0348783233.USD","02269","BK1161","01093","09995","LU0708995583.HKD","LU0823426480.USD","06978"],"gpt_icon":1},{"id":"2551216032","title":"2025全球制药50强排名揭晓，中国药企表现亮眼！","url":"https://stock-news.laohu8.com/highlight/detail?id=2551216032","media":"医药地理","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551216032?lang=zh_cn&edition=full","pubTime":"2025-07-15 19:46","pubTimestamp":1752580012,"startTime":"0","endTime":"0","summary":"近日，美国《制药经理人》杂志公布了2025全球制药企业50强排名。这一榜单依据2024年度处方药业务全球销售、核心产品收入以及研发投入等指标进行排名。中国药企上榜情况概览此次上榜的6家中国药企中，云南白药排名第33位，与去年持平，位居中国药企榜首。华东医药首次上榜，排名第41位。2025全球制药50强榜单中国药企的亮眼表现，是中国制药行业发展的一个重要里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715205051a44c7785&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715205051a44c7785&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","01276","06160","01177","SBHMY","600276","01093","ONC"],"gpt_icon":0},{"id":"2551156152","title":"医保商保双目录调整 生物医药午后涨幅扩大 荣昌生物涨逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551156152","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551156152?lang=zh_cn&edition=full","pubTime":"2025-07-15 14:18","pubTimestamp":1752560315,"startTime":"0","endTime":"0","summary":"截至发稿，荣昌生物涨8.37%，石药集团涨7.26%，诺诚健华涨6.95%，百济神州涨6.43%，中国生物制药涨4.61%，信达生物涨3.66%。消息面上，2025年国家基本医疗保险，生育保险和工伤保险药品目录及商业健康保险创新药品目录调整7月11日正式启动。世纪证券指出，创新药商保目录意味着国内医药多元支付体系重构，商业健康险将在创新药支付方面扮演更为重要的角色，高价创新药可及性有望进一步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071514191497a6a43d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071514191497a6a43d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1152091754.HKD","LU1226287529.USD","LU0315179316.USD","LU1969619763.USD","688235","IE00BZ08YR35.GBP","LU1807302812.USD","LU1993786604.SGD","IE0008368742.USD","06160","LU0326950275.SGD","LU1226287875.USD","LU1960683339.HKD","IE00BZ08YT58.USD","688331","IE00B031HY20.USD","01801","LU0140636845.USD","BK1161","LU1226288170.HKD","01093","BK1521","01177","688428","BK1515","09995","LU0501845795.SGD","BK1191","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","LU1226287792.SGD","LU1008478684.HKD","LU1226288253.USD","LU0072913022.USD","SBHMY","IE0008369823.USD","LU0880133367.SGD","09969","LU1951186391.HKD","ONC","BK1583","LU0067412154.USD","LU1152091168.USD","IE00B543WZ88.USD","BK1574","LU2328871848.SGD","SG9999004220.SGD"],"gpt_icon":0},{"id":"2551132044","title":"百济神州盘中异动 早盘股价大涨3.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551132044","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551132044?lang=zh_cn&edition=full","pubTime":"2025-07-15 09:46","pubTimestamp":1752543984,"startTime":"0","endTime":"0","summary":"2025年07月15日早盘09时46分，百济神州股票出现波动，股价大幅拉升3.08%。截至发稿，该股报157.200港元/股，成交量78.37万股，换手率0.06%，振幅3.21%。资金方面，该股资金流入8633.43万港元，流出2658.95万港元。百济神州股票所在的生物技术行业中，整体跌幅为0.13%。百济神州公司简介：百济神州是一家全球性、商业阶段的生物科技公司,专注于研究、开发、生产以及商业化创新型药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071509462497a65edd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071509462497a65edd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK1161","BK1588","LU1969619763.USD","BK1500","LU0588546209.SGD","LU0307460666.USD","688235","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2551909815","title":"7月14日百济神州-UAH溢价达62.22%，位居AH股溢价率第70位","url":"https://stock-news.laohu8.com/highlight/detail?id=2551909815","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551909815?lang=zh_cn&edition=full","pubTime":"2025-07-14 16:43","pubTimestamp":1752482632,"startTime":"0","endTime":"0","summary":"7月14日，上证指数涨0.27%，收报3519.65点，恒生指数涨0.26%，收报24203.32点。当日收盘，百济神州-UA股报225.94元，跌幅1.72%，H股报152.5港元，下跌1.04%。资料显示，百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714164921a44970fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714164921a44970fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526","06160"],"gpt_icon":0},{"id":"2551760188","title":"每日卖空追踪 | 百济神州 07月14日卖空量成交35.71万股，卖空比例为7.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551760188","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551760188?lang=zh_cn&edition=full","pubTime":"2025-07-14 16:30","pubTimestamp":1752481832,"startTime":"0","endTime":"0","summary":"百济神州北京时间07月14日，跌1.04%，卖空量成交35.71万股%，较上一交易日减少32.99%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714172803a6a868d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714172803a6a868d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","06160","LU0588546209.SGD","LU0307460666.USD","BK1500","LU2328871848.SGD","LU1969619763.USD","BK1583","BK1161"],"gpt_icon":0},{"id":"2551392215","title":"2025年上半年，NMPA批准创新药盘点","url":"https://stock-news.laohu8.com/highlight/detail?id=2551392215","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551392215?lang=zh_cn&edition=full","pubTime":"2025-07-14 09:40","pubTimestamp":1752457218,"startTime":"0","endTime":"0","summary":"2025年上半年，CDE共受理6213个品种，同比增长15.83%，化药仍为主体，达4087个品种；中药818个品种；生物制品1305个品种。按注册分类统计，1类创新药完成审评804个品种，其中IND完成审评746个品种，批准临床率约为95%；NDA完成审评61个品种，批准上市率约为89%。2类改良型新药完成审评239个品种，其中IND完成审评196个品种，批准临床率约为92%；NDA完成审评47个品种，批准上市率约为96%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714094241a448a6a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714094241a448a6a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","LU0405327148.USD","LU2488822045.USD","BK0188","BK0196","LU1655091616.SGD","LU1997245177.USD","LU1328615791.USD","LU1064130708.USD","LU1064131003.USD","LU2495084118.USD","LU2148510915.USD","LU1997245094.SGD","06160","BK0239","BK0012","LU0405327494.USD","BK0183","LU1997244956.HKD","600276","LU1969619763.USD","LU2328871848.SGD","BK0060","159992","BK0028"],"gpt_icon":0},{"id":"2551130912","title":"2025年医保政策与产业动态：产业布局升级与行业监管强化","url":"https://stock-news.laohu8.com/highlight/detail?id=2551130912","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551130912?lang=zh_cn&edition=full","pubTime":"2025-07-13 08:05","pubTimestamp":1752365100,"startTime":"0","endTime":"0","summary":"中国报告大厅网讯，随着国家医疗保障体系的不断完善，2025年医保相关政策及医药产业发展呈现显著变化。国家医保局、药监局等机构通过政策引导与严格监管，进一步优化药品供给结构，并强化了对违法违规行为的打击力度。数据显示，2025年目录调整将直接影响超万种药品的市场准入资格。总结2025年医保政策与产业布局呈现多维度深化态势：目录动态调整优化资源配置、监管强化保障行业规范、资本助力推动技术创新。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071308112797a3ed86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071308112797a3ed86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK0239","ONC","02315","688235"],"gpt_icon":0},{"id":"2550999933","title":"A股公司股东会面面观：中行、工行等大行透明度领跑，部分公司股东会存在一定要求","url":"https://stock-news.laohu8.com/highlight/detail?id=2550999933","media":"证券市场周刊市...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550999933?lang=zh_cn&edition=full","pubTime":"2025-07-12 13:28","pubTimestamp":1752298122,"startTime":"0","endTime":"0","summary":"在监管层引导和推动上市公司加强投资者关系工作的趋势下，央企尤其是国有大行的股东大会内容披露深度、报名方式和会议召开等工作领跑A股。相比之下，部分上市公司在股东大会报名渠道、披露内容透明度、会议地址等环节还有待加强，甚至有的上市公司明确要求股东不得携带手机进入会场。相比之下，中国平安、贵州茅台等公司在公告中未明确现场股东要求不得录音录像。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712134233a6a50cfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712134233a6a50cfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","SG9999001051.SGD","LU0173614495.USD","SG9999013353.USD","LU0307460666.USD","LU2449936058.SGD","BK1560","BK1231","IE00BVYPNQ40.USD","LU0823426308.USD","LU0359201612.USD","LU0417516902.SGD","IE0032431581.USD","LU1961090484.USD","IE00BVYPNP33.GBP","LU0039217434.USD","BK1500","LU0561508036.HKD","BK1588","LU0871576103.HKD","LU1880383440.USD","SG9999006597.SGD","SG9999007991.SGD","LU2399975544.HKD","LU0588546209.SGD","LU0327786744.USD","SGXZ90724238.SGD","SG9999001069.SGD","LU2328871848.SGD","LU0572944931.SGD","LU1969619763.USD","IE00BYV24P56.USD","LU0737861699.HKD","LU1224709979.USD","BK1161","LU0359201885.HKD","LU1720050803.USD","03143","06160","LU0359202008.SGD","LU0348827113.USD","LU0164880469.USD","IE00BGHQDM52.EUR","BK1583","LU2148611432.USD","LU1023057109.AUD","LU1794554557.SGD","01398","LU0348825331.USD","LU1880383366.USD"],"gpt_icon":0},{"id":"2550173990","title":"中国创新药：出海黄金时代 游到海水变蓝","url":"https://stock-news.laohu8.com/highlight/detail?id=2550173990","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550173990?lang=zh_cn&edition=full","pubTime":"2025-07-12 00:00","pubTimestamp":1752249600,"startTime":"0","endTime":"0","summary":"主因中国创新药实力增强，十年创新努力终开花结果。而与此同时，MNC重磅药物专利悬崖即将到来，大多现金充沛，BD迫在眉睫。预计中国出海BD持续蓬勃。免疫与炎症是仅次于肿瘤的第二大疾病领域，已涌现多款百亿美元级别重磅药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712202520a6a57a5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712202520a6a57a5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK0060","600276","LU1997244956.HKD","LU2148510915.USD","BK0188","BK0012","06160","BK0239","BK0183","LU1997245094.SGD","LU1328615791.USD","LU1655091616.SGD","BK0028","LU1997245177.USD","LU0405327494.USD","LU0405327148.USD","LU1064130708.USD","LU2488822045.USD","LU2495084118.USD","LU1064131003.USD","688266","159992","LU2328871848.SGD","688331","BK0196"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.1996},{"period":"1month","weight":0.1765},{"period":"3month","weight":0.3121},{"period":"6month","weight":0.4794},{"period":"1year","weight":0.972},{"period":"ytd","weight":0.6786}],"compareEarnings":[{"period":"1week","weight":0.0196},{"period":"1month","weight":0.0216},{"period":"3month","weight":0.1451},{"period":"6month","weight":0.251},{"period":"1year","weight":0.381},{"period":"ytd","weight":0.2213}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeiGene Ltd是一家全球生物技术公司，致力于为全球癌症患者发现和开发肿瘤治疗方法。该公司已发现并开发三种批准药物，包括BRUKINSA，一种布鲁顿酪氨酸激酶的小分子抑制剂，用于治疗各种血癌；TEVIMBRA（tislelizumab），一种抗PD-1抗体免疫疗法，用于治疗各种实体瘤和血癌；以及是聚ADP核糖聚合酶1(PARP1)和PARP2的选择性小分子抑制剂pamiparib。该公司已获得在美国、中华人民共和国（中国）、欧盟、英国、加拿大、澳大利亚和其他国际市场销售BRUKINSA，在欧盟和中国销售替雷利珠单抗，以及在中国销售帕米帕尼的批准。它还专注于在Amgen Inc独家授权下在中国商业化癌症药物，如XGEVA、BLINCYTO、KYPROLIS等。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.009815},{"month":2,"riseRate":0.571429,"avgChangeRate":0.046604},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.052519},{"month":4,"riseRate":0.428571,"avgChangeRate":0.037509},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.052709},{"month":6,"riseRate":0.428571,"avgChangeRate":0.007027},{"month":7,"riseRate":0.857143,"avgChangeRate":0.098944},{"month":8,"riseRate":0.833333,"avgChangeRate":0.065797},{"month":9,"riseRate":0.428571,"avgChangeRate":0.01247},{"month":10,"riseRate":0.571429,"avgChangeRate":-0.017395},{"month":11,"riseRate":0.571429,"avgChangeRate":0.120457},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.068807}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}